Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Characterizing Potentially Preventable Cancer- and Chronic Disease-Related Emergency Department Use in the Year After Treatment Initiation: A Regional Study.

Panattoni L, Fedorenko C, Greenwood-Hickman MA, Kreizenbeck K, Walker JR, Martins R, Eaton KD, Rieke JW, Conklin T, Smith B, Lyman G, Ramsey SD.

J Oncol Pract. 2018 Mar;14(3):e176-e185. doi: 10.1200/JOP.2017.028191. Epub 2018 Feb 8.

PMID:
29452549
2.

Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility.

Eaton KD, Romine PE, Goodman GE, Thornquist MD, Barnett MJ, Petersdorf EW.

J Thorac Oncol. 2018 May;13(5):649-659. doi: 10.1016/j.jtho.2018.01.022. Epub 2018 Mar 23.

PMID:
29408308
3.

A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.

King GT, Eaton KD, Beagle BR, Zopf CJ, Wong GY, Krupka HI, Hua SY, Messersmith WA, El-Khoueiry AB.

Invest New Drugs. 2018 Jan 15. doi: 10.1007/s10637-018-0560-6. [Epub ahead of print]

PMID:
29333575
4.

Pregnancy Screening in Patients With Cancer.

Gustafson AM, Goldfrank DJ, Dunson WA, Mulkerin DL, Caires RL, Eaton KD.

J Natl Compr Canc Netw. 2018 Jan;16(1):99-103. doi: 10.6004/jnccn.2017.7059. No abstract available.

PMID:
29295884
5.

Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies.

Rodriguez CP, Martins RG, Baik C, Chow LQ, Santana-Davila R, Goulart BH, Lee S, Eaton KD.

Head Neck. 2018 Mar;40(3):584-589. doi: 10.1002/hed.25020. Epub 2017 Dec 28.

PMID:
29283469
6.

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).

Awad MM, Chu QS, Gandhi L, Stephenson JJ, Govindan R, Bradford DS, Bonomi PD, Ellison DM, Eaton KD, Fritsch H, Munzert G, Johnson BE, Socinski MA.

Lung Cancer. 2017 Feb;104:126-130. doi: 10.1016/j.lungcan.2016.12.019. Epub 2016 Dec 30.

PMID:
28212994
7.

Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma.

Pellini Ferreira B, Redman M, Baker KK, Martins R, Eaton KD, Chow LQM, Baik CS, Goulart B, Lee SM, Santana-Davila R, Rodriguez CP.

Laryngoscope. 2017 Jul;127(7):1583-1588. doi: 10.1002/lary.26422. Epub 2016 Dec 1.

PMID:
27905113
8.

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.

Chow LQM, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Disis ML, Martins RG.

Clin Cancer Res. 2017 May 15;23(10):2442-2450. doi: 10.1158/1078-0432.CCR-16-1934. Epub 2016 Nov 3.

9.

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.

Ou SI, Govindan R, Eaton KD, Otterson GA, Gutierrez ME, Mita AC, Argiris A, Brega NM, Usari T, Tan W, Ho SN, Robert F.

J Thorac Oncol. 2017 Jan;12(1):145-151. doi: 10.1016/j.jtho.2016.09.131. Epub 2016 Sep 30.

10.

Value-Based Care in Lung Cancer.

Eaton KD, Jagels B, Martins RG.

Oncologist. 2016 Aug;21(8):903-6. doi: 10.1634/theoncologist.2016-0116. Epub 2016 Jun 2. No abstract available.

11.

Detection of HPV in oral rinse samples from OPSCC and non-OPSCC patients.

Dang J, Feng Q, Eaton KD, Jang H, Kiviat NB.

BMC Oral Health. 2015 Oct 15;15(1):126. doi: 10.1186/s12903-015-0111-x.

12.

A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.

Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, van den Heuvel MM, Lal R, Kloecker GH, Eaton KD, Chu Q, Dunlop DJ, Jain M, Garon EB, Davis CS, Carrier E, Moses SC, Shawler DL, Fakhrai H.

Eur J Cancer. 2015 Nov;51(16):2321-9. doi: 10.1016/j.ejca.2015.07.035. Epub 2015 Aug 14.

PMID:
26283035
13.

The Pseudocavitation Sign of Lung Adenocarcinoma: A Distinguishing Feature and Imaging Biomarker of Lepidic Growth.

Tailor TD, Schmidt RA, Eaton KD, Wood DE, Pipavath SN.

J Thorac Imaging. 2015 Sep;30(5):308-13. doi: 10.1097/RTI.0000000000000168.

PMID:
26258598
14.

Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric Patients.

Fang M, Becker PS, Linenberger M, Eaton KD, Appelbaum FR, Dreyer Z, Airewele G, Redell M, Lopez-Terrada D, Patel A, Rabin KR, Lu X.

Am J Clin Pathol. 2015 Aug;144(2):263-70. doi: 10.1309/AJCPW83OXPYKPEEN.

PMID:
26185311
15.

Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes.

Mellati M, Eaton KD, Brooks-Worrell BM, Hagopian WA, Martins R, Palmer JP, Hirsch IB.

Diabetes Care. 2015 Sep;38(9):e137-8. doi: 10.2337/dc15-0889. Epub 2015 Jun 26. No abstract available.

PMID:
26116720
16.

Spontaneous regression of non-small-cell lung cancer in AIDS after immune reconstitution.

Menon MP, Eaton KD.

J Thorac Oncol. 2015 Jan;10(1):e1-2. doi: 10.1097/JTO.0000000000000236. No abstract available.

17.

Occult primary, version 3.2014.

Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Schwab RB, Shulman LN, Smerage JB, Stevenson MM, Varadhachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Jul;12(7):969-74.

PMID:
24994917
18.

Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.

Pritchard CC, Salipante SJ, Koehler K, Smith C, Scroggins S, Wood B, Wu D, Lee MK, Dintzis S, Adey A, Liu Y, Eaton KD, Martins R, Stricker K, Margolin KA, Hoffman N, Churpek JE, Tait JF, King MC, Walsh T.

J Mol Diagn. 2014 Jan;16(1):56-67. doi: 10.1016/j.jmoldx.2013.08.004. Epub 2013 Nov 2.

19.

Plasma processing conditions substantially influence circulating microRNA biomarker levels.

Cheng HH, Yi HS, Kim Y, Kroh EM, Chien JW, Eaton KD, Goodman MT, Tait JF, Tewari M, Pritchard CC.

PLoS One. 2013 Jun 7;8(6):e64795. doi: 10.1371/journal.pone.0064795. Print 2013.

20.

Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.

Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, Yunus F, Kurland BF, Eaton KD, Liao JJ, Mendez E, Futran N, Wang DX, Chai X, Wallace SG, Austin M, Schmidt R, Hayes DN.

J Clin Oncol. 2013 Apr 10;31(11):1415-21. doi: 10.1200/JCO.2012.46.3299. Epub 2013 Mar 4.

PMID:
23460709

Supplemental Content

Loading ...
Support Center